Jane Street’s Aldeyra Therapeutics ALDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$111K Buy
65,800
+43,500
+195% +$191K ﹤0.01% 10584
2025
Q4
$116K Buy
+22,300
New +$115K ﹤0.01% 10109
2023
Q4
Sell
-57,700
Closed -$385K 9128
2023
Q3
$385K Sell
57,700
-38,600
-40% -$286K ﹤0.01% 6667
2023
Q2
$808K Buy
+96,300
New +$949K ﹤0.01% 5561
2022
Q2
Sell
-83,700
Closed -$372K 9562
2022
Q1
$372K Sell
83,700
-48,500
-37% -$193K ﹤0.01% 8027
2021
Q4
$529K Buy
132,200
+117,800
+818% +$898K ﹤0.01% 7152
2021
Q3
$126K Sell
14,400
-1,100
-7% -$10.1K ﹤0.01% 9164
2021
Q2
$176K Buy
+15,500
New +$186K ﹤0.01% 8924

Other funds holding ALDX

Jane Street's ALDX Position: Q1 2026 in Review

Jane Street increased its Aldeyra Therapeutics (ALDX) stake by 219% in Q1 2026, buying an estimated $2.91M and bringing the position to 968,891 shares worth $1.64M. The position accounts for ﹤0.01% of the portfolio, ranked #5465.

Jane Street first reported a position in ALDX in Q3 2017 and has held it in 21 quarters since. The position peaked at $2.68M in Q1 2023. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • Jane Street held 968,891 shares of Aldeyra Therapeutics worth $1.64M as of Q1 2026.
  • Jane Street bought 665,039 Aldeyra Therapeutics shares in Q1 2026, an estimated $2.91M.
  • Aldeyra Therapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #5465 holding.
  • Jane Street first reported a position in Aldeyra Therapeutics in Q3 2017 and has held it in 21 quarters since.
  • Jane Street's Aldeyra Therapeutics position peaked at $2.68M in Q1 2023.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.